Read More Pharma Industry News Novartis gets Pluvicto EC approval for advanced prostate cancer Novartis has received the approval of the European Commission (EC) for Pluvicto (lutetium (177Lu) vipivotide tetraxetan), a targeted… byRaghuram KadariDecember 15, 2022